IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
暂无分享，去创建一个
A. Broeks | K. Sikorska | E. Rozeman | C. Blank | J. Haanen | J. D. de Groot | P. Dimitriadis | D. van den Broek | S. Heijmink | S. Wilgenhof | B. A. Van de Wiel | M. Vollebergh | J. V. van Thienen | E. Hoefsmit | J. Versluis | B. Heeres | L. Grijpink-Ongering | A. Sari | Disha Rao | R. Lacroix | C. Flohil | M. Lopez-Yurda